By Dave Simpson ( September 18, 2018, 6:15 PM EDT) -- Biomedical firm Clovis Oncology Inc. and two of its executives will pay more than $20 million in penalties to resolve U.S. Securities and Exchange Commission claims that the company misled investors about the efficacy of its developmental lung cancer drug, the agency said Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.